

Contents

Clinical Instruments to Evaluate and Guide Treatment in Schizophrenia	1
Stephen R. Marder	
Cognitive Impairment in Schizophrenia	11
Richard S.E. Keefe and Philip D. Harvey	
Behavioral Animal Models to Assess Pro-cognitive Treatments for Schizophrenia	39
Jared W. Young, Nurith Amitai, and Mark A. Geyer	
Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia	81
Hsun-Hua Chou, Elizabeth Twamley, and Neal R. Swerdlow	
Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment	113
Colm M.P. O'Tuathaigh, Lieve Desbonnet, and John L. Waddington	
5-HT_{2C} Agonists as Therapeutics for the Treatment of Schizophrenia	147
Sharon Rosenzweig-Lipson, Thomas A. Comery, Karen L. Marquis, Jonathan Gross, and John Dunlop	
The Role of Dopamine D₃ Receptors in Antipsychotic Activity and Cognitive Functions	167
Gerhard Gross and Karla Drescher	
Nicotinic Mechanisms in the Treatment of Psychotic Disorders: A Focus on the $\alpha 7$ Nicotinic Receptor	211
Ann Olincy and Robert Freedman	
Muscarinic Mechanisms in Psychotic Disorders	233
David L. McKinzie and Frank P. Bymaster	

**Glutamatergic Synaptic Dysregulation in Schizophrenia:
Therapeutic Implications** 267
Joseph T. Coyle, Alo Basu, Michael Benneyworth, Darrick Balu,
and Glenn Konopaske

**Metabotropic Glutamate Receptors for New Treatments
in Schizophrenia** 297
E.J. Herman, M. Bubser, P.J. Conn, and C.K. Jones

**Glycine Transport Inhibitors in the Treatment
of Schizophrenia** 367
Daniel C. Javitt

**Nicotinic Receptors and Functional Regulation of GABA
Cell Microcircuitry in Bipolar Disorder and Schizophrenia** 401
Francine M. Benes

Development of Disease-Modifying Treatment of Schizophrenia 419
Anton Beshpalov, Corinna Klein, Berthold Behl, Gerhard Gross,
and Hans Schoemaker

Index 443

Contents of Volume 212

The Dopamine Dysfunction in Schizophrenia Revisited: New Insights into Topography and Course	1
Rebecca Kuepper, Mette Skinbjerg, and Anissa Abi-Dargham	
Role of Dopamine D₂ Receptors for Antipsychotic	27
Nathalie Ginovart and Shitij Kapur	
Dopamine Receptor Signaling and Current and Future Antipsychotic Drugs	53
Kevin N. Boyd and Richard B. Mailman	
Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics	87
Herbert Y. Meltzer	
Managing the Prodrome of Schizophrenia	125
W. Wolfgang Fleischhacker and Alexander M. Simma	
Metabolic Consequences of Antipsychotic Therapy: Preclinical and Clinical Perspectives on Diabetes, Diabetic Ketoacidosis, and Obesity	135
David J. Heal, Jane Gosden, Helen C. Jackson, Sharon C. Cheetham, and Sharon L. Smith	
Medical Needs in the Treatment of Psychotic Disorders	165
F. Markus Leweke, Thorsten M. Odorfer, and J. Malte Bumb	
Antipsychotics in the Treatment of Bipolar Disorder	187
Jaskaran Singh, Guang Chen, and Carla M. Canuso	
The Pharmacogenetics of Antipsychotic Treatment	213
Gavin P. Reynolds	

Interactions and Monitoring of Antipsychotic Drugs 241
Christoph Hiemke and Bruno Pfuhlmann

Delivery Systems and Dosing for Antipsychotics 267
Cara R. Rabin and Steven J. Siegel

Imaging as Tool to Investigate Psychoses and Antipsychotics 299
Jan Booij and Thérèse van Amelsvoort

Biomarkers for Antipsychotic Therapies 339
Emilio Merlo Pich, Gabriel Vargas, and Enrico Domenici

Behavioral Animal Models of Antipsychotic Drug Actions 361
Daria Peleg-Raibstein, Joram Feldon, and Urs Meyer

Index 407